Truist Securities Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $6
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Gregory Fraser has maintained a 'Buy' rating on Amneal Pharmaceuticals (NYSE:AMRX) and raised the price target from $4 to $6.
August 07, 2023 | 2:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amneal Pharmaceuticals' price target has been raised from $4 to $6 by Truist Securities, which maintains a 'Buy' rating on the stock.
The raised price target and maintained 'Buy' rating by Truist Securities indicates a positive outlook for Amneal Pharmaceuticals. This could potentially lead to an increase in the stock's price in the short term as it may boost investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100